Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 286-292

  Gorenflo, Matthias ^a,c   Ullmann, Michael V ^a   Herpel, Esther ^a   Neumayer, Stephan ^a   Dieckmann, Ralf ^a   Demirakca, Sueha ^b   Klimpel, Homa ^a   Hagl, Siegfried ^a   Gebhard, Martha Maria ^c  

^a University Medical Center

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Endothelin 1; Lung; Pulmonary hypertension; VEGF

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; MESSENGER RNA; PLACEBO; VASCULOTROPIN;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HEART OUTPUT; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; NONHUMAN; PERFUSION; PIGLET; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; VASCULAR DISEASE;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GENE EXPRESSION REGULATION; HYPERTENSION, PULMONARY; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; LUNG; PULMONARY ARTERY; PULMONARY CIRCULATION; PYRROLIDINES; RANDOM ALLOCATION; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548717741     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180a02ec3     Document Type: Article

References (34)

1. Celermajer DS, Cullen S, Deanfield JE. Impairment of endotheliumdependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:440-446.
2. Haworth SG. Pulmonary hypertension in childhood. Eur Respir J. 1993;6:1037-1043.
3. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
4. Oishi P, Azakie A, Harmon C, et al. Nitric oxide-endothelin-1 interactions after surgically induced acute increases in pulmonary blood flow in intact lambs. Am J Physiol Heart Circ Physiol. 2006;290:H1922-H1932.
5. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405.
6. B receptors in cardiovascular disease. Ann Rev Pharmacol Toxicol. 2007;47:12.1-12.29.
7. Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation. 2003;107:1329-1335.
8. Fratz S, Meyrick B, Ovadia B, et al. Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure. Am J Physiol Lung Cell Mol Physiol. 2004;287:L592-L597.
9. Hirose S, Hosoda Y, Furuya S, et al. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int. 2000;50:472-479.
10. Geiger R, Berger RMF, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol. 2000;191:202-207.
11. Mata-Greenwood E, Meyrick B, Soifer SJ, et al. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2003;285:L222-L231.
12. Norman P. Atrasentan Abbott. Curr Opin Investig Drugs. 2002;3:1240-1248.
13. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of endothelin A receptor in human ovarian carcinoma. Cancer Res. 2003;63:2447-2553.
14. Parviz M, Bousamra M II, Chammas JH, et al. Effects of chronic pulmonary overcirculation on pulmonary vascular tone. Ann Thorac Surg. 1999;67:522-527.
15. Wilkinson JL. Haemodynamic calculations in the catheter laboratory. Heart. 2001;85:113-120.
16. Gorenflo M, Vogel M, Hetzer R, et al. Morphometric techniques in the evaluation of pulmonary vascular changes due to congenital heart disease. Pathol Res Pract. 1996;192:107-116.
17. Cooney TP, Thurlbeck WM. The radial alveolar count method of Emery and Mithal: a reappraisal 1 - postnatal lung growth. Thorax. 1982;37:572-579.
18. Cailla HL, Vannier CJ, Delaage MA. Guanosine 3′,5′- cyclicmonophosphate assay at 10(-15)-mole level. Anal Biochem. 1976:70:195-202.
19. Capper SJ, Ella SJ, Kalinka S. Development and application of three radioimmunoassays of endothelin of varying specificities. J Cardiovasc Pharmacol. 1991;17(Suppl 7):S425-S426.
20. Feng S, Bogatcheva NV, Kamat AA, et al. Endocrine effects of relaxin overexpression in mice. Endocrinology. 2006;147:407-414.
21. Hömme M, Schmitt CP, Mehls O, et al. Mechanisms of mitogen-activated protein kinase inhibition by parathyroid hormone in osteoblast-like cells. J Am Soc Nephrol. 2004;15:2844-2850.
22. Coers W, Temens W, Kempinga C, et al. Specificity of antibodies to nitric oxide synthase isoforms in human, guinea pig, rat, and mouse tissue. J Histochem Cytochem. 1998;46:1385-1391.
23. Laufs U, Endres M, Stagliano N, et al. Neuroprotectin mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000;106:15-24.
24. McKenzie JE. Swine as a model in cardiovascular research. In: Tumbleson ME, Schook LB, eds. Advances in Swine in Biomedical Research. New York, NY: Plenum Press; 1996:7-11.
25. Stenbøg EV, Steinbrüchel DA, Thomsen AB, et al. The pulmonary vasculature in a neonatal porcine model with increased pulmonary blood flow and pressure. Cardiol Young. 2001;11:420-430.
26. Fratz S, Geiger R, Kresse H, et al. Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg. 2003;126:1724-1729.
27. Dschietzig T, Richter C, Bartsch C, et al. Flow induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun. 2001;289:245-251.
28. Rondelet B, Kerbaul F, Vivian GF, et al. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension. Pediatr Res. 2007;61:284-288.
29. Kavanagh M, Seaborn T, Crochetiere J, et al. Modulating effect of a selective endothelin A receptor antagonist on pulmonary endothelin system protein expression in experimental diaphragmatic hernia. J Pediatr Surg. 2005;40:1382-1389.
30. Fike C, Kaplowitz MR, Bousamra M 2nd. eNOS and prostanoid enzymes in lungs of newborn piglets with chronic aortopulmonary shunts. Am J Physiol Lung Cell Mol Physiol. 2001;281:L475-L482.
31. Fike CD, Aschner JL, Zhang Y, et al. Impaired NO signaling in small pulmonary arteries of chronically hypoxic newborn piglets. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1244-L1254.
32. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006;290:L209-L221.
33. Shehata SM, Mooi WJ, Okazaki T. Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Thorax. 1999;54:427-431.
34. Rondelet B, Kerbaul F, Van Beneden R, et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets. Effects of sildenafil therapy. Circulation. 2004;110:2220-2225.